There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Inspection Record
Phoenix Innovative Healthcare Manufactures Private Limited — FDA 483 Findings
Inspectors Steven A BrettlerThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design and suitably located to facilitate operations for its intended use.
Actual yield and percentages of theoretical yield are not determined at the conclusion of each appropriate phase of holding of the drug product.
Deviations from written production and process control procedures are not recorded and justified.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Glenmark Pharmaceuticals Inc USA2022-05-19 · US FDASimilar to finding 1 There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications…
- Packagina On Demand, Inc.2024-09-27 · US FDASimilar to finding 2 Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
- Lyophilization Services of New England, Inc. dba PCI Pharma Services2026-06-10 · US FDASimilar to finding 2 Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
- BSP Pharmaceuticals S.p.A.2022-03-31 · US FDASimilar to finding 2 Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
- Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.2025-03-07 · US FDASimilar to finding 1 There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been…
A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.